TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
B: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen
C: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group
D: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Renal Denervation in Patients With Refractory Hypertension
Brief Summary: To investigate the clinical utility of renal denervation in the treatment of refractory hypertension.


Options:
A: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen
B: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A
C: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Sympathetic Renal Denervation | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment with aldactone | Intervention Type: PROCEDURE; Name: Sympathetic Renal Denervation; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Treatment with aldactone; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, DB Controlled Study to Evaluate the Nutritional Safety (Growth) of an Amino Acid Based Formula With Prebiotics and Probiotics in Infants Diagnosed With Cow Milk Allergy, With or Without Other Food Allergies.
Brief Summary: This study involves the use of 2 different Neocate formulas: a control formula called Neocate Infant and a test Neocate formula. These kinds of formulas are for use in children from birth to 8 months of age with Cow Milk Allergy (CMA), other food allergies, and other gastrointestinal disorders. The purpose of this study is to compare the control and test Neocate formulas for safety, tolerability, and effectiveness (in promoting growth) when used in subjects with CMA.

This study will also look at the test Neocate formula to see if it is hypoallergenic when used in subjects with CMA.


Options:
A: Arm Label: Amix; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amix | Intervention Type: DIETARY_SUPPLEMENT; Name: Amix; Assigned to Arm(s): Amix
B: Arm Label: New Neocate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: new Neocate | Arm Label: Neocate Infant; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Neocate Infant | Intervention Type: DIETARY_SUPPLEMENT; Name: Neocate Infant; Assigned to Arm(s): Neocate Infant | Intervention Type: DIETARY_SUPPLEMENT; Name: new Neocate; Assigned to Arm(s): New Neocate
C: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: New Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: New Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
D: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.
Brief Summary: The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.


Options:
A: Arm Label: MI and Medication review; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Treatment, Behavioral: MI and Medication review | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): MI and Medication review, Standard treatment | Intervention Type: BEHAVIORAL; Name: MI and Medication review; Assigned to Arm(s): MI and Medication review
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminders of medicines intake | Intervention Type: BEHAVIORAL; Name: SMS reminders of medicines intake; Assigned to Arm(s): Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Basic medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Basic medication therapy management | Arm Label: Enhanced medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced medication therapy management | Intervention Type: BEHAVIORAL; Name: Basic medication therapy management; Assigned to Arm(s): Basic medication therapy management | Intervention Type: BEHAVIORAL; Name: Enhanced medication therapy management; Assigned to Arm(s): Enhanced medication therapy management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.
Brief Summary: The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.


Options:
A: Arm Label: Peer-Led Stroke Recurrence Prevention Education; Type: EXPERIMENTAL; Interventions: Behavioral: Prevent Return of Stroke | Arm Label: Usual Care (Delayed Intervention); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Prevent Return of Stroke | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Peer-Led Stroke Recurrence Prevention Education | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Usual Care (Delayed Intervention)
B: Arm Label: Regular care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Support program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient centered structured support program | Intervention Type: BEHAVIORAL; Name: Patient centered structured support program; Assigned to Arm(s): Support program
C: Arm Label: Usual Home Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nurse Practitioner + Health Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Practitioner Only, Behavioral: Nurse Practitioner + Health Coach | Arm Label: Nurse Practitioner Only; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse Practitioner Only | Intervention Type: BEHAVIORAL; Name: Nurse Practitioner Only; Assigned to Arm(s): Nurse Practitioner + Health Coach, Nurse Practitioner Only | Intervention Type: BEHAVIORAL; Name: Nurse Practitioner + Health Coach; Assigned to Arm(s): Nurse Practitioner + Health Coach
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.
Brief Summary: The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: AF Clinic; Type: EXPERIMENTAL; Interventions: Other: AF Clinic | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Care as Usual | Intervention Type: OTHER; Name: AF Clinic; Assigned to Arm(s): AF Clinic | Intervention Type: OTHER; Name: Care as Usual; Assigned to Arm(s): Care as Usual
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2
D: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Proactive Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt: a Randomised Controlled Trial
Brief Summary: The purpose of this study is to determine the case manager are effective in the treatment of suicide attempters.


Options:
A: Arm Label: active anodal tDCS to ventrolateral prefrontal cortex (VLPFC); Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: sham anodal tDCS to VLPFC; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: Discontinued prior to randomization; Type: OTHER; Interventions: Other: No intervention | Intervention Type: DEVICE; Name: Transcranial direct current stimulation; Assigned to Arm(s): active anodal tDCS to ventrolateral prefrontal cortex (VLPFC), sham anodal tDCS to VLPFC | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Discontinued prior to randomization
B: Arm Label: Brief Cognitive Behavioral Therapy (BCBT); Type: EXPERIMENTAL; Interventions: Behavioral: Brief Cognitive Behavioral Therapy (BCBT) | Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: Brief Cognitive Behavioral Therapy (BCBT); Assigned to Arm(s): Brief Cognitive Behavioral Therapy (BCBT) | Intervention Type: BEHAVIORAL; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU)
C: Arm Label: BI 1358894 5mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 25mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 75mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: BI 1358894 125mg; Type: EXPERIMENTAL; Interventions: Drug: BI 1358894 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1358894; Assigned to Arm(s): BI 1358894 125mg, BI 1358894 25mg, BI 1358894 5mg, BI 1358894 75mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: case management; Type: EXPERIMENTAL; Interventions: Other: proactive psychosocial intervention by care managers, Behavioral: case management | Intervention Type: OTHER; Name: proactive psychosocial intervention by care managers; Assigned to Arm(s): case management | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): case management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Proactive Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt: a Randomised Controlled Trial
Brief Summary: The purpose of this study is to determine the case manager are effective in the treatment of suicide attempters.


Options:
A: Arm Label: case management; Type: EXPERIMENTAL; Interventions: Other: proactive psychosocial intervention by care managers, Behavioral: case management | Intervention Type: OTHER; Name: proactive psychosocial intervention by care managers; Assigned to Arm(s): case management | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): case management
B: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
C: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention; Assigned to Arm(s): Teachable Moment Brief Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Proactive Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt: a Randomised Controlled Trial
Brief Summary: The purpose of this study is to determine the case manager are effective in the treatment of suicide attempters.


Options:
A: Arm Label: case management; Type: EXPERIMENTAL; Interventions: Other: proactive psychosocial intervention by care managers, Behavioral: case management | Intervention Type: OTHER; Name: proactive psychosocial intervention by care managers; Assigned to Arm(s): case management | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): case management
B: Arm Label: Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): Care Management | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): Skills Training | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: PS CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Problem solving cognitive behaviour therapy (PS CBT) | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem solving cognitive behaviour therapy (PS CBT); Assigned to Arm(s): PS CBT
D: Arm Label: Dialectical Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Inidividual and Group Supportive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual and Group Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Individual and Group Supportive Therapy; Assigned to Arm(s): Inidividual and Group Supportive Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: YUKON-drug-eluting Stent Below The Knee - Prospective Randomized Double-blind Multicenter Study
Brief Summary: The purpose of this study is to compare the effectiveness of the treatment with balloon-expandable YUKON-BTX-Sirolimus-eluting stent over the treatment with YUKON-BTX uncoated stent in patients with ischemic infrapopliteal arterial disease.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: XIENCE V everolimus eluting coronary stent system | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: MULTILINK VISION coronary stent system | Intervention Type: DEVICE; Name: XIENCE V everolimus eluting coronary stent system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: MULTILINK VISION coronary stent system; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Implantation of YUKON Sirolimus-eluting Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Implantation of YUKON Stent (uncoated) | Intervention Type: DEVICE; Name: Implantation of YUKON Sirolimus-eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Implantation of YUKON Stent (uncoated); Assigned to Arm(s): 2
C: Arm Label: balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: balloon angioplasty | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: drug eluting stent | Intervention Type: DEVICE; Name: balloon angioplasty; Assigned to Arm(s): balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting stent; Assigned to Arm(s): Drug eluting stent
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Efficacy, and Optimal Dosage of Soy Isoflavones to Prevent Osteoporosis
Brief Summary: The purpose of this study is to determine whether soy isoflavone supplementation is safe and effective to prevent bone loss in postmenopausal women.


Options:
A: Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation + dietary soy counseling; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Conjugated equine estrogen +/- medroxyprogesterone acetate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cimicifuga racemosa; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Trifolium pratense; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Red clover; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 3

Answer: D